Tildrakizumab| ChemScene
Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis[2].IC50 & Target:IL-23In Vitro:Tildrakizumab inhibits IL-23-induced STAT3 signaling in HeLa cells expressed the human IL-23Rα and IL-12Rβ1 receptors, with an IC50 of 23 pM[2].
Tildrakizumab reduces IL-23’s affinity for IL-23Rα through a negative allosteric modulation[2].
In Vivo:Tildrakizumab (100?mg/kg, s.c., every 2 weeks up to 9 months) is well tolerated in cynomolgus monkeys (toxicity studies).
Trivial name | Tildrakizumab |
Catalog Number | CS-0620821 |
Alternative Name(s) | SCH 900222; MK 3222; Anti-Human IL23 Recombinant Antibody |
Molecular Formula | 1000 |
CAS# | 1326244-10-3 |
Purity | >98% |
Condensed Formula | N/A |
Size | 1mg |
Supplier Page | www.chemscene.com/1326244-10-3.html |